Prof Robert E Coleman, MD, MBBS, FRCP is an expert in Oncology at University of Sheffield (United Kingdom). As of October 2026, ScienceLeadR ranks Robert E Coleman in the top 1% of experts worldwide for Breast Diseases and Breast Neoplasms. Robert E Coleman has authored 197 publications, the most recent in 2026, and is an investigator in 15 clinical trials. SLR score: 775 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Robert E Coleman, MD, MBBS, FRCP University of Sheffield United Kingdom
775 ScienceLeadR Reputation 775
Network Map

Oncology

Subspecialties: Hematology - Biochemistry - Dermatology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2002 - 2026

Source: PubMed

University of Sheffield

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 197

Citations

Citations: 19 473 1st author: 20 Last author: 50 Unique author: 22


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Bone Health in Oncology: Defining Biosimilar Denosumab Use Through Multidisciplinary Collaboration.
PMID 42926077 — pain, neoplasms, denosumab, neoplasm metastasis, therapeutics, hematologic diseases, biosimilar pharmaceuticals
Crit Rev Oncol Hematol20260
Effect of Contrasting Redox Potential Evolutions and Cap Management Techniques on the Chemical Composition of Red Wine.
PMID 40807345 — injections, biological evolution, air, automation, wine, glutathione
Molecules20255
Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG.
PMID 40726588 — aromatase, aromatase inhibitors, breast neoplasms, risk assessment, neoplasms, hormones, breast, therapeutics
J Bone Oncol20258
Mapping the Metastatic Landscape: A Population-Based Cohort Study for Prognostic Insights Into Newly Diagnosed Stage IV Breast Cancer Cases.
PMID 40655317 — lung, breast neoplasms, brain, neoplasms, cohort studies, neoplasm metastasis, breast, therapeutics, prognosis
Cancer Innov20250
NMNAT1 Binding at Promoters and Enhancers Couples NAD + Synthesis to RNA Polymerase II Engagement.
PMID 40654636 — cells, genes, promoter regions, genetic, nad, chromatin, rna polymerase ii, enzymes, dna-directed rna polymerases, enhancer elements, genetic, rna
bioRxiv20251

Clinical Studies 15

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1 Study Chair: 3

By phase:

Phase 3 8
Phase 2 5
N/A 1
Phase 2/Phase 3 1

By status:

Completed 11
Unknown 2
Active not recruiting 1
Terminated 1

By type:

Interventional 15

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 0
multicentricup10 12

Main Topics

LeadR Networks

Main global connection map